Nanograb
Nanograb is a computational drug discovery company leveraging AI to generate optimal binder combinations for disease treatment. Their product enables highly targeted drug delivery to specific areas of the body. The company is founded by a team of scientists with extensive experience in computational biophysics and antibody design, including a PhD from Imperial College London and a Senior Lecturer. They aim to translate their scientific expertise into a groundbreaking product in the drug discovery field.
Nanograb
Nanograb is a computational drug discovery company leveraging AI to generate optimal binder combinations for disease treatment. Their product enables highly targeted drug delivery to specific areas of the body. The company is founded by a team of scientists with extensive experience in computational biophysics and antibody design, including a PhD from Imperial College London and a Senior Lecturer. They aim to translate their scientific expertise into a groundbreaking product in the drug discovery field.
TL;DR
Founded: 2023
Headquarters: San Francisco, CA
Business: AI-driven computational drug discovery designing combinations of molecular binders
Stage: Pre-Seed
Lead investor: Y Combinator
Employee count: Approximately 7
Company Overview
Problem Domain
Drug discovery; targeted therapeutic delivery using designed molecular binders.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
125000
Reported pre-seed/seed financing in Sep 2023; some sources obfuscate amount while Dealroom lists $125k.
Investor Signal
“Y Combinator listed as lead investor on disclosed pre-seed round”